Publications by authors named "M Vaisvilas"
Detection of neuronal antibodies for autoimmune encephalitis and paraneoplastic neurological syndromes relies on commercially available cell-based assays and lineblots. However, lineblots may reveal the presence of neuronal antibodies in patients with various non-autoimmune etiologies. Herein we describe patients with non-autoimmune etiologies (cohort B) and detectable neuronal antibodies and compare them to definite cases of autoimmune encephalitis (cohort A) for differences in clinical data.
View Article and Find Full Text PDFObjective: To assess the differences of treatment outcomes regarding disease activity in patients with highly active relapsing multiple sclerosis (RMS), treated with autologous hematopoietic stem cell transplantation (HSCT) or alemtuzumab (ATZ).
Methods: Open-label prospective single-center observational cohort study, enrolling patients with highly active RMS for treatment with ATZ or HSCT between 2014 and 2021.
Results: A total of 50 patients (31/50 (62 %) in HSCT vs 19/50 (38 %) in ATZ group) were included.
Paraneoplastic neurological syndromes (PNSs) comprise a subset of immune-mediated nervous system diseases triggered by an underlying malignancy. Each syndrome usually shows a distinct clinical presentation and outcome according to the associated neural antibodies. PNSs generally have a subacute onset with rapid progression and severe neurological disability.
View Article and Find Full Text PDFArticle Synopsis
- Tumefactive multiple sclerosis (TmMS) is a rare form of demyelinating disease that can mimic strokes, but detailed information about patients is limited.
- A systematic review of 39 articles identified 41 patients with TmMS, showing that the majority were diagnosed with multiple sclerosis variants (vMS) or inflammatory demyelinating variants (vInf).
- vInf cases exhibited more severe neurological decline and higher fatality rates compared to vMS, indicating the need for tailored treatments and closer monitoring for those with vInf.
Paraneoplastic neurological syndromes (PNSs) comprise a subset of immune-mediated nervous system diseases triggered by an underlying malignancy. Each syndrome usually shows a distinct clinical presentation and outcome according to the associated neural antibodies. PNSs generally have a subacute onset with rapid progression and severe neurological disability.
View Article and Find Full Text PDF